-
公开(公告)号：US11458124B2
公开(公告)日：2022-10-04
申请号：US17058973
申请日：2019-07-08
Applicant: UCB Biopharma SRL
Inventor： Gareth Neil Brace , Daniel Christopher Brookings , Gregory Foulkes , Fabien Claude Lecomte
IPC: C07D405/14 , A61K31/422 , A61K31/352 , A61K31/407 , A61K31/4155 , A61K31/4245 , A61K31/427 , A61K31/437 , C07D311/96 , C07D405/12 , C07D413/12 , C07D491/107 , C07D491/20 , C07D493/10
Abstract: A series of substituted spirocyclic indane derivatives of Formula (I), and analogues thereof, being potent modulators of human IL-17 activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including inflammatory and autoimmune disorders.
-
公开(公告)号：US20220280887A1
公开(公告)日：2022-09-08
申请号：US17631897
申请日：2020-07-30
Applicant: UCB BIOPHARMA SRL
Inventor： NEIL ALAN WATSON , CURTIS WILLIAM PHIPPEN
Abstract: The invention relates to the field of manufacturing recombinant antibody molecules. In particular, methods of purifying such recombinant antibody molecules are provided wherein imidazole or an imidazole-analogue is added during the elution of the recombinant antibody molecule from an affinity chromatography resin, such as a protein-A-based resin.
-
公开(公告)号：US20220251064A1
公开(公告)日：2022-08-11
申请号：US17621871
申请日：2020-06-29
Applicant: UCB Biopharma SRL
Inventor： Anne Valade
IPC: C07D401/06
Abstract: The present invention relates to compounds according to formula (I), which are a positive allosteric modulators of D1 and accordingly of benefit as pharmaceutical agents for the treatment of diseases in which D1 receptors play a role.
-
公开(公告)号：US11407835B2
公开(公告)日：2022-08-09
申请号：US16300522
申请日：2017-05-11
Applicant: UCB BIOPHARMA SRL
Inventor： Andrew Jeffrey Yates , Jan Ivo Massant
Abstract: The present invention relates to pharmaceutical compositions comprising an antibody or a fragment thereof suitable for freeze-drying (i.e. lyophilizing). The pharmaceutical compositions, which comprise an antibody or an antigen-binding fragment thereof; from 1% to 20% w/v sucrose; an amino acid or a mixture of amino acids; and surfactant, are provided as pharmaceutical compositions for freeze-drying; as freeze-dried (i.e. lyophilized) compositions which can be reconstituted into a solvent at the time of use or as reconstituted liquid formulations ready for administration.
-
公开(公告)号：US20220220192A1
公开(公告)日：2022-07-14
申请号：US17585174
申请日：2022-01-26
Applicant: UCB BIOPHARMA SRL
Inventor： Ralph ADAMS , Patrick DOWNEY , Terence Seward BAKER , Kerry Louise TYSON , Lorenzo DE LICHTERVELDE , Daniel John LIGHTWOOD , David James MCMILLAN
IPC: C07K16/18
Abstract: The present invention relates to antibodies binding alpha synuclein and fragments thereof capable of binding alpha synuclein as a monomer and in fibrils and preventing alpha synuclein aggregation induced by alpha synuclein fibrils. The antibodies of the present invention are for use in the treatment of alpha synucleinopathies, including Parkinson's disease.
-
Patent Agency Ranking
公开(公告)号：US11345760B2
公开(公告)日：2022-05-31
申请号：US15321055
申请日：2015-06-25
Applicant: UCB BIOPHARMA SRL
Inventor： Pallavi Bhatta , Emma Dave , Sam Philip Heywood , David Paul Humphreys
IPC: C07K16/46
Abstract: The present disclosure relates to a multi-specific antibody molecule comprising or consisting of: a) a polypeptide chain of formula (I): VH—CH1—X—V1; and b) a polypeptide chain of formula (II): VL-CL-Y—V2 and pharmaceutical formulations comprising, for example for use in treatment. The disclosure also provides polynucleotide sequences encoding said multispecific antibody molecules, vectors comprising the polynucleotides and host cells comprising said vectors and/or polynucleotide sequences. There is a provided a method of expressing a multispecific antibody molecule of the present disclosure from a host cell.
-
公开(公告)号：US20220144941A1
公开(公告)日：2022-05-12
申请号：US17286247
申请日：2019-10-16
Applicant: UCB BIOPHARMA SRL
Inventor： Melissa Kaye Brock , William James Byrnes , Bernhard Heinrich Greve , Claus Peter Kiessling , Grant Langdon , Elizabeth Webster Manis
IPC: C07K16/28 , A61K39/395 , A61P21/04
Abstract: The disclosure relates to a method of treating or preventing Myasthenia Gravis (MG) in a human in need thereof using an anti-FcRn antibody or antigen binding fragment thereof. In particular, the method provides suitable dosage regimens for such treatment.
-
公开(公告)号：US11292831B2
公开(公告)日：2022-04-05
申请号：US16772043
申请日：2018-12-13
Applicant: UCB Biopharma SRL
Inventor： Patrick Downey , Kerry Louise Tyson , Marco Kriek , Lorenzo De Lichtervelde , Daniel John Lightwood , David James McMillan , Peter Charles Elliott , Terence Seward Baker
Abstract: The present invention relates to alpha synuclein binding antibodies and fragments thereof capable of binding alpha synuclein as a monomer and in fibrils and preventing alpha synuclein aggregation induced by alpha synuclein fibrils. The antibodies of the present invention are for use in the treatment of alpha synucleinopathies, including Parkinson's disease.
-
公开(公告)号：US11261242B2
公开(公告)日：2022-03-01
申请号：US16771993
申请日：2018-12-13
Applicant: UCB Biopharma SRL
Inventor： Ralph Adams , Patrick Downey , Terence Seward Baker , Kerry Louise Tyson , Lorenzo De Lichtervelde , Daniel John Lightwood , David James McMillan
Abstract: The present invention relates to antibodies binding alpha synuclein and fragments thereof capable of binding alpha synuclein as a monomer and in fibrils and preventing alpha synuclein aggregation induced by alpha synuclein fibrils. The antibodies of the present invention are for use in the treatment of alpha synucleinopathies, including Parkinson's disease.
-
公开(公告)号：US20220025033A1
公开(公告)日：2022-01-27
申请号：US17500616
申请日：2021-10-13
Applicant: UCB BIOPHARMA SRL , SANOFI
Inventor： Alastair David Griffiths LAWSON , Daniel John LIGHTWOOD , Rebecca Jayne MUNRO , James Philip O'CONNELL , John Robert PORTER
IPC: C07K16/24
Abstract: It has been demonstrated that certain compounds bind to TNF and stabilise a conformation of trimeric TNF that binds to the TNF receptor. Antibodies which selectively bind to complexes of such compounds with TNF superfamily members are disclosed. These antibodies may be used to detect further compounds with the same activity, and as target engagement biomarker.
-
-
-
-
-
-
-
-
-
Search Results
209
records
(took 0.025 seconds)
